^
Association details:
| Biomarker: | RET mutation |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug Class: | RET inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Published date:
09/13/2021
Excerpt:
Two pts with BRAF mutated ATC received treatment with dabrafenib + trametinib, reaching an ORR of 100% and median PFS of 10 months. Five pts with RET mutated medullary thyroid cancer were treated with a selective RET inhibitor, achieving an ORR of 80%....Targeted therapy resulted in outstanding response rates and may have a significant survival benefit in aggressive tumors, such as ATC.
